A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the main causes of cancer-related death. Sorafenib, which is the first-line therapy for this disease, is associated with reduced therapeutic efficacy that could potentially be overcome by combination with selumetinib. In this context, the main goa...

Descripción completa

Detalles Bibliográficos
Autores principales: Farinha, Dina, Migawa, Michael, Sarmento-Ribeiro, Ana, Faneca, Henrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141275/
https://www.ncbi.nlm.nih.gov/pubmed/34040370
http://dx.doi.org/10.2147/IJN.S302288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141275/
https://www.ncbi.nlm.nih.gov/pubmed/34040370
http://dx.doi.org/10.2147/IJN.S302288

Ejemplares similares